Pliant Therapeutics Prepares for Major Respiratory Congress
Pliant Therapeutics Announces Upcoming Presentations
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a leader in developing novel therapeutics for fibrotic diseases, has announced four significant presentations at the European Respiratory Society (ERS) International Congress 2024. This event will be held in Vienna, showcasing groundbreaking research in respiratory health and treatment options.
Presentation Details
Late Breaker – Oral and ePoster Presentations
The first presentation will focus on evaluating the antifibrotic activity of bexotegrast, a dual ?V?6/?V?1 integrin inhibitor. This study, presented by Dr. Martin Decaris from Pliant Therapeutics, examines the effect of bexotegrast using precision cut-lung slices derived from non-IPF interstitial lung disease explants. The session is scheduled for September 8, with a focus on new insights into sarcoidosis.
Later Breaker – Oral and ePoster Presentations
Another compelling presentation will cover the impact of bexotegrast on type 1 collagen deposition in idiopathic pulmonary fibrosis (IPF) patients after 12 weeks of therapy. Dr. Sydney B. Montesi from Massachusetts General Hospital will present this important research as part of a session dedicated to advances in clinical practice for rare interstitial diseases.
Safety and Tolerability of Bexotegrast
Oral and Poster Presentations
Pliant Therapeutics will also share findings from Phase 2 trials on the safety and tolerability of bexotegrast in patients with IPF and primary sclerosing cholangitis (PSC). Dr. Gregory Cosgrove from the company will lead this presentation on September 9, discussing novel management strategies that could reshape treatment for pulmonary fibrosis.
Poster Presentation on Biomarkers
Additionally, a poster presentation will focus on post-hoc biomarker analysis in IPF participants receiving bexotegrast over a 12-week period. Dr. Martin Decaris will deliver insights on this analysis during the session on the pathogenesis of pulmonary fibrosis and serum biomarkers on September 10.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is dedicated to the discovery and development of treatments for fibrotic diseases. Its lead product candidate, bexotegrast (PLN-74809), aims to provide innovative solutions for conditions such as IPF and PSC. The company has achieved Fast Track Designation and Orphan Drug Designation from the U.S. FDA for these conditions. Furthermore, Pliant has initiated the BEACON-IPF trial, a pivotal Phase 2b/3 trial exploring the efficacy of bexotegrast.
As part of its clinical advancements, Pliant is also progressing with PLN-101095, a new small molecule aimed at targeting solid tumors, and has regulatory clearance for a Phase 1 study of PLN-101325, which focuses on muscular dystrophies.
Contact Information
For more information, please visit Pliant Therapeutics' website. Investor and media inquiries can be directed to Christopher Keenan, Vice President of Investor Relations and Corporate Communications at Pliant Therapeutics, Inc. via email at ir@pliantrx.com.
Frequently Asked Questions
What is the focus of the upcoming presentations by Pliant Therapeutics?
The presentations will cover innovative research on the antifibrotic activity of bexotegrast, a treatment for fibrotic diseases.
When will the European Respiratory Society International Congress take place?
The congress will take place from September 7 to September 11, 2024.
Where can I find more information about Pliant Therapeutics?
More information can be found on Pliant Therapeutics' official website.
What is bexotegrast?
Bexotegrast is Pliant's lead product candidate, designed as a dual selective inhibitor targeting integrins associated with fibrotic diseases.
Who should contact Pliant Therapeutics for investor inquiries?
Investor inquiries should be directed to Christopher Keenan, Vice President of Investor Relations and Corporate Communications.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.